Department of Hematology/Oncology, Cell and Gene Therapy - IRCCS, Bambino Gesù Children's Hospital, Rome, Italy.
Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, Rome, Italy.
Clin Cancer Res. 2024 Aug 15;30(16):3361-3363. doi: 10.1158/1078-0432.CCR-24-0486.
Over the past decade, chimeric antigen receptor T cells have emerged as a breakthrough cancer therapy in selected hematologic malignancies. Translating the success of this therapy to solid tumors is challenging. In this issue, we discuss strategies potentially useful to increase the chimeric antigen receptor T-cell efficacy in this clinical indication. See related article by Fischer-Riepe et al., p. 3564.
在过去的十年中，嵌合抗原受体 T 细胞在某些血液恶性肿瘤的治疗中取得了突破性进展。然而，将这种治疗方法应用于实体瘤仍然具有挑战性。在本期中，我们讨论了一些可能有助于提高嵌合抗原受体 T 细胞在这一适应证中的疗效的策略。有关 Fischer-Riepe 等人的相关文章，见 3564 页。
